Triple Drug Trial
February 26, 2010

The Progeria Research Foundation launched their triple drug trial in August, 2009. The goal is for three drugs to complement one another in stopping the production of the abnormal protein progerin which causes Progeria. The three drugs are Pravastatin, Zoledronic acid, and Lonafarnib. The trial will last two and a half years. In the clip below, Audrey Gordon, President and Executive Director of PRF, discusses how this second trial is different from the first:

Advertisements